Management tracks: Obsidian builds out team; plus Agilvax, Selvita, NeuBase and more
Obsidian Therapeutics (Cambridge, Mass.) hired Catherine Stehman-Breen as chief development officer, Ryan Daws as CFO, and Karen Brown as SVP, intellectual property and legal affairs. Stehman-Breen was CMO of Atlas Venture-backed Dyne Therapeutics Inc. (Cambridge, Mass.) and Disarm Therapeutics Inc. (Cambridge, Mass.). Daws was a managing director of the healthcare investment banking group at Baird. Brown was VP and chief intellectual property counsel at Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) (see “Obsidian: Fine-tuning Therapeutic Protein Expression with Approved Drugs”).
Antibody-based cancer company AgilVax Inc. (Albuquerque, N.M.) hired Joseph Patti as president and CEO, succeeding Federica Pericle, who resigned. Patti was president and CEO of Aviragen Therapeutics (NASDAQ:AVIR); he also co-founded Inhibitex Inc. and served as CSO and SVP of R&D from 2007 until it was acquired by Bristol-Myers Squibb Co. (NYSE:BMY) in 2012...